Chapter 4
The Pandemic We Refused to See
As COVID-19 made its way to American shores, officials struggled with limited testing capabilities and an incomplete understanding of the threat's magnitude. On January 19, a 35-year-old man who had recently returned from visiting family in Wuhan sought medical care in Snohomish County, Washington. After testing negative for flu, his travel history triggered immediate concern. His case was reported to the CDC's Emergency Operations Center-the only place in America capable of testing for the novel coronavirus at that time.
When confirmed positive on January 20, he was transported to a special biocontainment ward originally built for Ebola patients, becoming America's first known COVID case. Fifty close contacts were quarantined but none developed infections, temporarily suggesting successful containment. This created a false sense of security that the virus could be contained through targeted measures.
Meanwhile, in Washington DC, White House officials harbored growing concerns about containment prospects. National Security Adviser Robert O'Brien warned President Trump on January 28 that this would be "the biggest national security threat you face in your presidency." Matthew Pottinger, O'Brien's deputy who had reported on the 2003 SARS outbreak as a journalist in China, was receiving alarming firsthand accounts contradicting official narratives from Beijing and WHO. His Chinese doctor contacts revealed community spread across multiple provinces, with one estimating half of Wuhan cases were asymptomatic.
The true extent of spread became apparent on February 28 when a second Seattle case emerged with no connection to the first. Using genetic sequencing, Dr. Trevor Bedford of Fred Hutchinson Cancer Research Center determined the viral strains differed by only two small mutations, suggesting the virus had been circulating undetected for six weeks. This pioneering use of "genetic epidemiology" indicated hundreds might already be infected in Washington State, revealing a substantial undetected outbreak.
Dr. Helen Chu, an infectious disease specialist at the University of Washington, had been collecting nasal swabs from Seattle residents with flu symptoms since January as part of the Seattle Flu Study. When they finally received permission on March 4 to test their January and February samples, they found SARS-CoV-2 in 1.1 percent of specimens-a shocking number given official claims that coronavirus wasn't yet in communities. The virus was already spreading widely in Seattle while HHS officials assured the White House there was no community transmission.
Chapter 5
The CDC's Testing Catastrophe
The CDC's pandemic playbook placed it at the center of all response efforts-first to access viral samples, first to design tests, first to screen samples nationally, and first to develop test kits for state public health labs. Commercial manufacturers were expected to wait their turn in this sequential process. The CDC designed its COVID test in just seven days after China published the genetic sequence on January 11, and confirmed the first U.S. case in Seattle on January 19.
While other countries like Thailand, South Korea, and Taiwan quickly fielded their own tests, and the WHO endorsed a German-designed test by mid-January, the CDC insisted on using its own design, claiming the European test might fail to detect viral mutations. Though the CDC posted its test blueprint on January 24, it declared that only the CDC could conduct testing, treating SARS-CoV-2 as a special pathogen requiring exclusive control.
When the CDC's test kits finally shipped, they didn't work, leaving the entire country dependent on a single CDC lab for all testing. The problems started early-after quality checks on February 3 showed issues with the N3 reagent and a February 6 check revealed the test failed 33% of the time, the CDC inexplicably shipped the kits to labs in thirty-three states anyway. When public health labs received the kits, 24 of the first 26 labs couldn't get them to work, with sterile water incorrectly testing positive for coronavirus.
Despite Scott Becker of the Association of Public Health Laboratories requesting permission to use the test without the problematic N3 component on February 9, the CDC insisted on manufacturing new batches of the component rather than simply removing it. By mid-February, it became clear that contamination at the CDC's manufacturing site had affected multiple test components, revealing the agency's lack of manufacturing expertise and quality control systems.
The CDC's insistence on manufacturing its own test kits rather than contracting with commercial manufacturers from the outset proved disastrous. By February 16, with both N1 and N3 components showing contamination, the CDC considered either changing test sensitivity thresholds or dropping the N3 component entirely. Despite the FDA's growing urgency and preference for dropping N3, the CDC repeatedly delayed making a decision. Finally, on February 26, the CDC agreed to let labs use just N1 and N2 components, but by then many labs had already destroyed their kits.
The CDC's test failure stemmed from contamination of its reagents with coronavirus RNA. Both the N3 and N1 components were contaminated when someone likely carried genomic material from a "dirty" room into the clean manufacturing area. This meant the test was detecting its own contamination rather than actual COVID-19 cases. The agency violated basic lab practices by producing synthetic SARS-CoV-2 RNA in the same facility where test kits were assembled-a risk they took to save just ten days, but which ultimately cost six critical weeks.
Chapter 6
Looking for the Virus in All the Wrong Places
Without diagnostics, officials relied on the CDC's Influenza Like Illness surveillance system (ILI)-a network of labs reporting respiratory specimen data. This system was fundamentally unsuited for detecting COVID because it was backward-looking, insensitive to small outbreaks, relied on delayed Medicare claims data, and couldn't detect asymptomatic spread. With 50,000 non-flu respiratory samples weekly during flu season, early COVID cases easily hid within normal variation.
The CDC's approach to information resembles academic epidemiology rather than crisis management. During COVID, the CDC's thorough but delayed analyses in their Morbidity and Mortality Weekly Report often came months after critical decisions had to be made by patients, providers, and policymakers. This reflected not a lack of competence but the agency's institutional style, structure, and culture that prioritized definitive analysis over timely, if imperfect, guidance.
The information desert extended to clinical practice, with no reliable system tracking American doctors' treatment approaches and patient outcomes. The best clinical data came from Italy and China, which did a superior job collecting and sharing timely information. The CDC relied heavily on death certificate data, which typically lagged by one to two months, while European countries extracted near real-time insights from electronic health records to guide clinical decisions.
Critical epidemiological data was lacking, preventing targeted mitigation. The CDC's guidance on quarantine periods and distancing requirements seemed arbitrary without transparency about their limited scientific foundation. Without reliable data collection systems, policymakers defaulted to influenza-based approaches that often didn't apply to COVID.
The CDC's approach to genomic surveillance was woefully inadequate. Despite Deborah Birx's spring 2020 request to establish contracts with outside labs for widespread sequencing, the CDC insisted on keeping this work in-house, limiting capacity to hundreds rather than thousands of samples monthly. While the UK sequenced 10-60% of patient samples, the US managed just 0.3%, ranking 43rd globally in sequencing percentage.
Chapter 7
Preparing for the Wrong Pandemic
The modern application of mitigation approaches was first developed in 2005 to counter the threat of H5N1 bird flu. This deadly virus had claimed over 50% of its victims and found reservoirs in migratory waterfowl. The 2005 plan viewed NPIs as temporary measures to slow spread until vaccines or antivirals could be developed. Unlike general pandemic planning, this approach targeted a specific threat-H5N1-though the measures could be adjusted based on severity.
Based on historical analysis of the 1918 Spanish flu pandemic, researchers formulated a "targeted layered containment" approach combining multiple tactics. This began with case-focused interventions like isolation and quarantine, supplemented by social distancing measures including school closures, workplace modifications, and canceling mass gatherings. Their research showed these measures wouldn't prevent most infections but could "flatten the curve" to prevent healthcare systems from being overwhelmed.
By February 2020, HHS Secretary Azar presented the White House with a "doctrine" for addressing COVID-19 based on pandemic planning and lessons from the 2019 "Crimson Contagion" exercise. This simulation had revealed concerning gaps: federal agencies fighting over leadership, shortages of protective equipment, and states refusing CDC directives. Azar's plan shifted significant responsibility to states, giving them latitude to develop different strategies while maintaining mitigation as a core principle.
Our mitigation measures, designed for pandemic flu, proved remarkably effective against influenza while failing to contain COVID. The Southern Hemisphere saw flu cases plummet-Argentina recorded just 53 cases in 2020 compared to 4,623 in 2019, Chile dropped from 5,000 to 12, and South Africa from 1,094 to 6. By January 2021, the CDC had recorded only 1,316 positive flu cases compared to nearly 130,000 the previous year.
The stark difference highlighted how COVID's transmission patterns fundamentally differed from influenza's. While flu typically spreads from one person to two or three others after symptoms appear, COVID spread far more broadly through superspreading events and asymptomatic transmission. These superspreader incidents-like the Biogen conference that led to 300,000 downstream infections or a single choir practice that infected 53 of 61 attendees-demonstrated COVID's capacity for explosive aerosol transmission in indoor settings.
Chapter 8
South Korea's Success vs. America's Failure
South Korea's preparation for pandemic threats proved prescient. In December 2019, just before COVID-19 emerged, they conducted a tabletop exercise simulating a family returning from China with a mysterious respiratory disease that began spreading. This drill, implemented after their 2015 MERS experience, enabled rapid development of testing methodology when COVID became reality a month later.
Unlike the US, South Korea was well-prepared for COVID-19. Both countries identified their first cases in mid-January, but South Korea rapidly deployed widespread testing, identified clusters, and flattened their curve without strict shutdowns. They never ran short of testing supplies or protective equipment, having stockpiled materials for years. Their first wave peaked at 851 daily cases on March 3, then declined quickly.
Just one week after identifying their first COVID case, South Korean officials convened 20 diagnostics companies at Seoul's main train station, asking them to develop tests immediately. Their FDA had established a fast-track approval process after MERS. Two manufacturers were already developing tests, with Kogene Biotech receiving clearance just four days after the meeting, followed by Seegene Technologies a week later. The government guaranteed reimbursement, reducing financial risk, and provided manufacturers with viral samples and standardized assays for validation.
South Korea pioneered drive-through testing centers after Dr. Kim Jin-yong recognized that indoor testing sites required 30-minute ventilation periods between patients. The first drive-through center opened February 23 at Kyungpook National University's Chilgok Hospital, processing up to six patients hourly versus just two at indoor sites. By April 1, about 80 drive-through sites operated nationwide, strategically located away from hospitals to prevent healthcare facilities from becoming infection hubs as happened in Italy.
By early March, America faced a critical choice between following South Korea's successful containment path or Italy's spiraling epidemic. Unfortunately, we ended up following Italy's trajectory rather than South Korea's more successful model.
Chapter 9
Operation Warp Speed: A Rare Success Story
As soon as Chinese researchers posted the first genetic sequence of the novel coronavirus on January 10, 2020, labs across the US and Europe began developing vaccines. COVID arrived precisely when science had advanced to permit fully synthetic vaccines created from viral sequence data alone-without requiring actual virus samples. This technological breakthrough allowed vaccine design to begin as essentially a computational exercise, though it also exposed gaps in production and distribution capacity needed to quickly protect global populations.
In the early 1990s, scientists wondered if they could use genomic information to make vaccines directly from viral sequences. Initial efforts using DNA plasmids worked in animals but failed in humans as immune cells destroyed the genetic material too quickly. Researchers turned to messenger RNA (mRNA), which serves as a courier between DNA and cellular protein-making machinery. mRNA offered advantages: cells could more readily absorb it through endocytosis, its smaller size reduced immune destruction, and manufacturing required no animal or cellular components-just a chemical process.
I witnessed Pfizer's vaccine development from inside the boardroom. BioNTech's vaccine design proved remarkably effective by using the full-length spike protein, which generated antibodies against multiple regions rather than just one specific area. This approach fortuitously provided protection even as the virus mutated. Pfizer began pivotal trials on July 27, and on November 8, CEO Albert Bourla shared the stunning results with the board: the vaccine was over 90% effective at preventing COVID symptoms. It was an emotional moment-COVID was now a preventable disease.
Pfizer filed for emergency authorization on November 20, just 248 days after starting development-the fastest vaccine development in history. The company committed over $2 billion to the project, purchasing specialized mRNA manufacturing equipment at $200 million per unit before knowing if the vaccine would work. Unlike other companies, Pfizer declined federal development funding to avoid bureaucratic constraints that might slow their progress.
Chapter 10
Pandemic as National Security: A New Doctrine
In April 2000, the Clinton administration made the unprecedented move of designating HIV/AIDS a national security risk-the first time a naturally occurring infectious disease received such classification. The declaration marked a pivotal shift in how we view public health threats in relation to national defense. Intelligence estimates had concluded that HIV's spread through Eastern Europe wasn't just a humanitarian crisis but a geopolitical threat with potential to destabilize regions and trigger conflicts requiring American intervention.
We've oscillated between viewing public health through a national security lens and treating it as separate. The CDC's Epidemic Intelligence Service was deliberately named in 1952 to position the agency as a security asset, but this orientation eroded starting in the 1960s. During COVID, the Pentagon initially resisted reprogramming biodefense resources against a naturally occurring virus, leaving no agency fully owning homeland protection from these threats.
Our commitment to pandemic preparedness as a security priority has fluctuated dangerously across administrations. The National Security Council's biodefense function has been repeatedly established, disbanded, and reinstated-most recently eliminated in 2018 shortly before COVID struck. This volatility reflects our ambivalence toward treating naturally occurring biological threats as security concerns.
If we aim not just to mitigate but to prevent the next pandemic entirely, we must integrate our public health response with our national security apparatus and intelligence capabilities. America's dismal experience with COVID leaves us little choice but to expand our information-gathering tools. Our goal shouldn't be merely to blunt future impacts, but to ensure a calamity on COVID's scale never happens again by involving our instruments of national security.
The COVID pandemic marked the first large-scale use of genomic sequencing to track viral evolution and spread. While it's difficult to deduce behavior from sequence alone, key insights can be inferred-like SARS-CoV-2's ability to bind well to ACE2 receptors and its resemblance to SARS-1. As we expand sequence data and correlate genetic features with clinical outcomes, the predictive power of these tools will grow dramatically.
Sequencing can now identify emerging threats and predict viral activity in near real-time. Harvard is developing a sentinel surveillance system to detect novel pathogens in hot zones before they evolve into pandemics. The CDC is expanding sequencing for surveillance, including through the National Wastewater Surveillance System that monitors municipal sewage as a "liquid biopsy" of community health.
The COVID pandemic marked multiple historical turning points beyond just genomic advances. It revealed America's capacity to develop countermeasures at unprecedented speed-creating effective vaccines in under a year compared to the previous record of four years for mumps. Yet it simultaneously exposed catastrophic gaps in our public health infrastructure: shortages of basic supplies like masks and swabs, CDC's testing failures, and inability to efficiently distribute vaccines and therapeutics once developed.
We must now view pandemic preparedness through a national security lens, leveraging intelligence agencies to gather critical information about emerging threats, as international agreements alone proved insufficient. We need greater resilience in our public health infrastructure, expanded healthcare capacity for crisis response, massive diagnostic testing capabilities, and large-scale biological manufacturing. Despite being perceived as the best-prepared nation, America suffered tremendously with over 600,000 deaths. Looking ahead, we must recognize that while COVID was devastating, the next pandemic could be worse-potentially from a novel bird flu strain like H5N1 or H7N9. We succeeded scientifically with COVID but failed on the human aspects of response, permanently altering our society. How we learn and change will determine our future vulnerability.
